220 related articles for article (PubMed ID: 34190436)
1. Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A; Tawadros T; Lucca I; Herrera F; Bourhis J; Burruni R; Gomes MN; Codeluppi C; Jolliet L; La Rosa S; Meuwly JY; Jichlinski P; Berthold D; Valerio M
Investig Clin Urol; 2021 Jul; 62(4):416-422. PubMed ID: 34190436
[TBL] [Abstract][Full Text] [Related]
2. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
3. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer.
Thurtle D; Barrett T; Thankappan-Nair V; Koo B; Warren A; Kastner C; Saeb-Parsy K; Kimberley-Duffell J; Gnanapragasam VJ
BJU Int; 2018 Jul; 122(1):59-65. PubMed ID: 29438586
[TBL] [Abstract][Full Text] [Related]
4. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
5. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Amin A; Scheltema MJ; Shnier R; Blazevski A; Moses D; Cusick T; Siriwardena A; Yuen B; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
J Urol; 2020 May; 203(5):910-917. PubMed ID: 31825297
[TBL] [Abstract][Full Text] [Related]
6. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
9. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
10. Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
Doan P; Scheltema MJ; Amin A; Shnier R; Geboers B; Gondoputro W; Moses D; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
J Urol; 2022 Nov; 208(5):1028-1036. PubMed ID: 35947521
[TBL] [Abstract][Full Text] [Related]
11. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
12. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
13. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
Gallagher KM; Christopher E; Cameron AJ; Little S; Innes A; Davis G; Keanie J; Bollina P; McNeill A
BJU Int; 2019 Mar; 123(3):429-438. PubMed ID: 30113755
[TBL] [Abstract][Full Text] [Related]
14. A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up.
Song SH; Kim JK; Lee H; Lee S; Hong SK; Byun SS
Investig Clin Urol; 2021 Jan; 62(1):32-38. PubMed ID: 33258324
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
16. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
[TBL] [Abstract][Full Text] [Related]
17. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
Pepe P; Garufi A; Priolo G; Pennisi M
World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
Porpiglia F; Manfredi M; Mele F; Cossu M; Bollito E; Veltri A; Cirillo S; Regge D; Faletti R; Passera R; Fiori C; De Luca S
Eur Urol; 2017 Aug; 72(2):282-288. PubMed ID: 27574821
[TBL] [Abstract][Full Text] [Related]
19. Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.
Salguero J; Gómez-Gómez E; Valero-Rosa J; Carrasco-Valiente J; Mesa J; Martin C; Campos-Hernández JP; Rubio JM; López D; Requena MJ
Korean J Radiol; 2021 Apr; 22(4):559-567. PubMed ID: 33289358
[TBL] [Abstract][Full Text] [Related]
20. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?
Hu JC; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Sonn G; Dorey FJ; Marks LS
J Urol; 2014 Aug; 192(2):385-90. PubMed ID: 24512956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]